Clinical Trials Logo

Lymphoproliferative Disorders clinical trials

View clinical trials related to Lymphoproliferative Disorders.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06309823 Completed - Clinical trials for X-linked Lymphoproliferative Syndrome Type 2 (XLP-2)

A Single-patient Clinical Trial of MAS825 in a Patient With XIAP Deficiency

Start date: February 8, 2023
Phase: Phase 3
Study type: Interventional

MAS825 is a bi-specific IgG1 monoclonal antibody that simultaneously targets IL-1 beta and IL-18, thereby neutralizing both cytokines that are thought to be integral to the pathogenesis of XLP-2. Clinical trials are currently examining its efficacy in other diseases associated with elevations of these cytokines, including NLRC4-associated disease and hidradenitis suppurativa. This study proposes to assess the effectiveness of MAS825 in a single patient with XLP-2, who has previously demonstrated response to blockade of IL-1 beta and IL-18. Given the lack of alternative pharmaceutical options for XLP-2, this represents the only known medication option that avoids the toxicity associated with high-dose corticosteroids and the morbidity associated with hematopoietic stem cell transplantation.

NCT ID: NCT06042400 Completed - Anxiety Clinical Trials

Trial of Written Exposure for Metastatic Cancer Patients (EASE)

Start date: April 18, 2022
Phase: N/A
Study type: Interventional

In the face of imminent loss, many adults with metastatic cancer report a range of mental health challenges, including cancer-related trauma symptoms, fear of cancer progression and dying/death, anxiety, depression, and hopelessness, as well as physical symptoms such as fatigue and pain. Cancer patients may report feeling upset or haunted by imagined scenarios in a way that causes them distress and lowers their quality of life. This study aims to look at the acceptability and feasability of a writing-based intervention for adults with late-stage or recurrent cancer, or actively treated blood cancer. The EASE study uses a writing-based approach to address an individual's worst-case scenario about cancer because previous studies have shown that similar approaches have shown promise in reducing fear in early-stage cancer survivors and among adults with PTSD (posttraumatic stress disorder). The EASE study represents a novel adaptation of this foundational work on written exposure therapy (WET) to address worst-case scenarios among adults with late stage cancers. The EASE study will include 5 weekly one-on-one online video sessions with a trained therapist where participants will be coached through writing exercises based on a worst-case scenario related to their cancer experience.

NCT ID: NCT05557422 Completed - Clinical trials for Chronic Lymphoproliferative Diseases (CLPD)

BD OneFlow CLPD Panel (BD OneFlow LST, and B-CLPD T1 to T4 Assays) on the BD FACSLyric System.

Start date: October 12, 2022
Phase:
Study type: Observational

Multi-site, prospective performance study to determine equivalency between the investigational CLPD Full Panel on the FACSLyric system versus the final clinical diagnosis.

NCT ID: NCT05032313 Completed - Clinical trials for Chronic Lymphoproliferative Diseases (CLPD)

Evaluation of the Chronic Lymphoproliferative Diseases Limited Panel on the BD FACSLyric™ Flow Cytometer

Start date: April 26, 2021
Phase:
Study type: Observational

Multi-site, prospective performance study to determine equivalency between the investigational CLPD Limited Panel on the FACSLyric system versus the final clinical diagnosis.

NCT ID: NCT04463615 Completed - Clinical trials for Refractory Lymphoproliferative Disorder

Leflunomide for the Treatment of Relapsed or Refractory CD30+ Lymphoproliferative Disorders

Start date: May 5, 2021
Phase: Phase 2
Study type: Interventional

This trial studies how well leflunomide works for the treatment of patients with CD30+ lymphoproliferative disorders that have come back (relapsed) or do not respond to treatment (refractory). Leflunomide may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT03744676 Completed - Lymphoma Clinical Trials

A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)

Start date: November 29, 2018
Phase: Phase 2
Study type: Interventional

This is an open-label, multicenter, Phase 2 study to determine the safety, PK, and efficacy of lisocabtagene maraleucel (JCAR017) in subjects who have relapsed from, or are refractory to, two lines of immunochemotherapy for aggressive B-cell non-Hodgkin lymphoma (NHL) in the outpatient setting. Subjects will receive treatment with JCAR017 and will be followed for up to 2 years.

NCT ID: NCT03546101 Completed - Clinical trials for Post-transplant Lymphoproliferative Disorder

Early Detection of Epstein-Barr Virus Related Disease.

Start date: November 1, 2017
Phase:
Study type: Observational

Epstein-Barr virus (EBV) is one of several herpesviruses that cause disease in humans. EBV virus has an oncogenic potential, and it has been associated with the development of a wide range of cancers. Previous studies have shown a close association between EBV and Post-Transplant Lymphoproliferative disorder (PTLD) in transplant recipients. As part of a preventive approach against PTLD, several transplantation units now monitor the occurrence of EBV-DNAemia after transplantation. However, there is little evidence to guide this strategy; nor is there consensus concerning either the best specimen to use for EBV analysis (whole blood or plasma). In this study investigators aim to optimise and validate a polymerase chain reaction (PCR)-test for EBV-DNA on, respectively, whole blood, plasma and a combination of plasma and lymphocytes. The investigators wish to determine which of the three tests best predicts current and future risk of development of EBV-related diseases such as mononucleosis and PTLD.

NCT ID: NCT03513328 Completed - Sickle Cell Disease Clinical Trials

Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation

Start date: June 15, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

In this study, the investigators test 2 dose levels of thiotepa (5 mg/kg and 10 mg/kg) added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG) to determine the minimum effective dose required for reliable engraftment for subjects undergoing hematopoietic stem cell transplantation for non-malignant disease.

NCT ID: NCT03397706 Completed - Clinical trials for Lymphoproliferative Disorders

Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies

Start date: March 29, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

A two part, Phase 1b/2 study to define a recommended Phase 2 dose of VRx-3996 in combination with valganciclovir (Phase 1b) designed to evaluate the efficacy of this combination in relapsed/refractory EBV+ lymphomas.

NCT ID: NCT03392142 Completed - Clinical trials for Stem Cell Transplant Complications

Tabelecleucel for Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab

MATCH
Start date: December 29, 2017
Phase: Phase 3
Study type: Interventional

This is a multicenter, open label, single-arm, phase 3 study to assess the efficacy and safety of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of allogeneic hematopoietic cell transplant (HCT) after failure of rituximab.